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ABSTRACT	  	  Influenza	  virus	  remains	  a	  significant	  concern	  to	  public	  health,	  as	  there	  is	  a	  continued	   potential	   for	   a	   high	   fatality	   pandemic.	   Multiple	   strains	   of	   influenza	  have	  emerged	  that	  are	  resistant	  to	  antiviral	  therapeutics	  currently	  on	  the	  market.	  One	  approach	   to	  an	  antiviral	   therapeutic	   is	   to	   inhibit	   cleavage	  activation	  of	   the	  influenza	   virus	   hemagglutinin	   (HA).	   The	   viral	   HA	  must	   be	   cleaved	   by	   host	   cell	  proteases	  in	  order	  to	  fuse	  with	  the	  cell	  membrane	  during	  virus	  entry	  and	  is	  most	  likely	   driven	   by	   extracellular	   or	   membrane	   bound	   trypsin-­‐like	   proteases.	   One	  such	  inhibitor	  of	  these	  proteases	  is	  hepatocyte	  growth	  factor	  activator	  inhibitor-­‐2	  (HAI-­‐2).	   We	   show	   that	   HAI-­‐2	   has	   the	   potential	   to	   be	   used	   as	   an	   antiviral	  therapeutic	   for	   influenza	   and	   other	   viruses	   with	   similar	   entry	   mechanisms
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Abstract	  
	  Influenza	  virus	  remains	  a	  significant	  concern	  to	  public	  health,	  as	  there	  is	  a	  continued	  potential	  for	  a	  high	  fatality	  pandemic.	  Multiple	  strains	  of	  influenza	  have	  emerged	  that	  are	  resistant	  to	  the	  antiviral	  therapeutics	  currently	  on	  the	  market.	  One	  approach	  to	  an	  antiviral	  therapeutic	  is	  to	  inhibit	  cleavage	  activation	  of	  the	  influenza	  virus	  hemagglutinin	  (HA).	  The	  viral	  HA	  is	  synthesized	  as	  a	  fusion-­‐inactive	  precursor	  (HA0)	  that	  must	  be	  cleaved	  by	  host	  cell	  proteases	   in	  order	   to	   fuse	  with	   the	  cell	  membrane	  during	  virus	  entry.	  HA	  cleavage	   is	  most	   likely	   driven	   by	   extracellular	   or	   membrane	   bound,	   trypsin-­‐like	   proteases.	   By	  targeting	   host	   cell	   proteases	   that	   cleave	   the	  HA	   protein,	   cell	   infection	   by	   influenza	   virus	  could	  be	  stopped.	  An	   inhibitor	   of	   serine	   proteases	   is	   hepatocyte	   growth	   factor	   activator	   inhibitor-­‐2	  (HAI-­‐2).	  HAI-­‐2	  contains	  a	  Kunitz-­‐type	  inhibitor	  domain	  that	  has	  been	  found	  to	  be	  a	  potent	  inhibitor	  of	  a	  number	  of	  trypsin-­‐like	  serine	  proteases.	  HAI-­‐2	  can	  be	  used	  to	  inhibit	  cleavage	  of	  HA	   in	  vitro.	   HAI-­‐2	   administration	   to	  mice	   shows	  decreased	   viral	   titer	   in	  mice.	   Finally,	  data	   showing	   HAI-­‐2	   prevention	   of	   spread	   of	   human	   parainfluenza	   virus-­‐1,	   which	   has	   a	  similar	   activation	  mechanism	   to	   influenza,	   shows	   promise	   in	   utilizing	  HAI-­‐2	   as	   a	   broad-­‐range	  antiviral	  therapeutic	  for	  viruses	  similar	  to	  influenza.	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Background	  
	  
Influenza	  Virus	  	   Influenza	  causes	  a	  contagious	  respiratory	  illness	  that	   infects	  the	  upper	  respiratory	  tract	   and	   sometimes	   the	   lower	   respiratory	   tract.	   Common	   symptoms	   include	   sneezing,	  headache,	  coughing,	  and	  fever	  (1).	  Children,	  the	  elderly,	  and	  the	  immunocompromised	  are	  most	  at	  risk	  for	  more	  serious	  complications	  such	  as	  pneumonia	  and	  dehydration,	  which	  can	  result	  in	  hospitalization	  or	  death	  (1).	  The	  World	  Health	  Organization	  (WHO)	  estimates	  that	  5%	   to	   10%	   of	   adults	   and	   20%	   to	   30%	   of	   children	   are	   infected	   by	   influenza	   (1).	   In	   the	  United	  States	  alone,	  over	  200,000	  people	  are	  hospitalized	  due	  to	  influenza	  annually	  (1).	  As	  well	  as	  health	  concerns,	  influenza	  also	  exerts	  a	  significant	  economic	  burden	  on	  healthcare	  systems.	   In	   the	  United	  States,	  annual	  direct	  and	   indirect	  costs	  related	   to	   influenza	  due	   to	  hospitalization	  and	  productivity	  losses	  was	  estimated	  to	  be	  16.3	  billion	  dollars	  in	  2003	  (2).	  	   There	   are	   three	   types	   of	   influenza	   virus:	   influenza	  A,	   influenza	  B,	   and	   influenza	  C	  (1).	   They	   are	   classified	   by	   antigen	   variation	   in	   their	   nucleoprotein	   (NP)	   and	  matrix	   (M)	  protein	   (1).	   Influenza	   A	   and	   B	   are	   responsible	   for	   most	   of	   the	   infections	   observed	   in	  humans,	   while	   influenza	   C	   is	   antigenically	   stable	   and	   only	   causes	   a	   mild	   illness	   (1).	  However,	  influenza	  A	  raises	  the	  most	  public	  health	  concern	  among	  the	  three.	  	   Influenza	  A	  is	  found	  in	  a	  variety	  of	  organisms,	  from	  birds	  to	  pigs	  to	  humans	  (3).	  It	  is	  divided	   into	   subtypes	   based	   on	   two	   of	   its	   surface	   proteins,	   hemagglutinin	   (HA)	   and	  neuraminidase	   (NA).	   There	   are	   currently	   18	   known	   HA	   subtypes	   and	   11	   known	   NA	  subtypes	   (3).	   The	   large	   variance	   of	   influenza	   A	   subtypes	   occurs	   because	   it	   can	   undergo	  genetic	  changes	  via	  antigenic	  shift	  or	  antigenic	  drift.	  Antigenic	  drift	  occurs	  when	  mutations	  occur	  in	  the	  genome,	  changing	  the	  amino	  acids	  in	  the	  antigenic	  portions	  of	  the	  HA	  and	  NA	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proteins	  (4).	  When	  two	  strains	  of	  influenza	  infect	  the	  same	  host,	  antigenic	  shift	  can	  occur.	  Antigenic	   shift	   occurs	   when	   two	   different	   strains	   of	   influenza	   exchange	   their	   genetic	  material.	  Since	   influenza	  has	  a	  segmented	  genome,	   it	   is	  able	  to	  recombine	  creating	  a	  new	  subtype	  (4).	  This	  reassortment	  introduces	  a	  novel	  virus	  that	  can	  occasionally	  become	  more	  virulent	  and	  can	  cause	   influenza	  pandemic	  (4).	  A	  pandemic	  occurs	  when	  a	  new	  influenza	  strain	   enters	   the	   population	   that	   is	   different	   from	   seasonal	   virus	   strains,	   meaning	   the	  population	  has	  not	  built	  up	  any	   immunity	  against	   it.	   In	   the	   last	   century,	   there	  have	  been	  four	  pandemics	  caused	  by	  influenza	  A:	  the	  Spanish	  Flu	  of	  1918,	  the	  Asian	  Flu	  of	  1957,	  the	  Hong	  Kong	  Flu	  of	  1968,	  and	  the	  2009	  H1N1	  “swine	  flu”	  (1).	  
Influenza	  Structure	  and	  Replication	  	   Influenza	   is	   a	   segmented,	   negative	   sense,	   single-­‐stranded	   RNA	   virus	   (1).	   Its	  segmented	  genome	  is	  enclosed	  within	  a	  host-­‐derived	  lipid	  membrane,	  which	  has	  a	  variety	  of	   surface	  proteins	  embedded	   in	   it	   (Figure	  1.1A).	  The	   two	  major	  surface	  proteins	  are	  HA	  and	   NA.	   HA	   is	   important	   in	   viral	   entry	   and	   fusion	   with	   the	   host	   cell	   membrane	   (5).	   It	  originally	   exists	   in	   a	   pre-­‐cleaved	   form,	   HA0	   (1).	   The	   NA	   protein	   is	   responsible	   for	   viral	  release	   from	  the	  cell	   (1).	  There	  are	  also	  a	  variety	  of	  other	  proteins	   that	  contribute	  to	   the	  structure	  and	  replication	  of	  the	  influenza	  virus.	  The	  NP	  contributes	  to	  the	  structure	  of	  the	  viral	  capsid.	  The	  matrix	  1	  (M1)	  protein	  forms	  a	  coat	  under	  the	  viral	  envelope	  that	  mediates	  the	   encapsulation	   of	   the	   RNA-­‐nucleoprotein	   cores	   into	   the	  membrane	   envelope	   (1).	   The	  matrix	  2	   (M2)	  protein	   is	  an	   ion	  channel,	  which	  helps	   to	  maintain	   the	  pH	  across	   the	  viral	  membrane	  during	  entry	  and	  maturation	  of	  the	  viral	  capsid	  (1).	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   In	  order	  for	  an	  influenza	  virus	  particle	  to	  enter	  a	  host	  cell,	  it	  must	  first	  bind	  to	  sialic	  acid	  glycoproteins	  found	  at	  the	  surface	  of	  host	  cells	  (Figure	  1.1B)	  (5).	  The	  HA	  protein	  binds	  to	   sialic	   acid,	   initiating	   receptor-­‐mediated	   endocytosis	   and	   bringing	   the	   virus	   to	   the	  endosome	  (8).	  Before	   the	  virus	  particle	   is	  enveloped	  by	   the	  endosome,	   the	  HA	  protein	   is	  cleaved	  by	  host	  cell	  proteases	  (8).	  	  A	  variety	  of	  type	  II	  transmembrane	  serine	  proteases	  (TTSP),	  such	  as	  TMPRSS2	  and	  human	  airway,	  trypsin-­‐like	  protease	  (HAT)	  have	  been	  shown	  to	  cleave	  the	  HA	  protein	  (7,	  9).	  These	  proteases	  are	  expressed	  in	  the	  human	  lung	  and	  have	  the	  potential	  to	  cleave	  HA	  in	  
vivo	  (7).	  TTSPs	  play	  a	  large	  role	  in	  maintaining	  epithelial	  homeostasis	  in	  epithelial	  tissues	  as	   well	   as	   initiating	   proteolytic	   cascades	   and	   hormone	   or	   growth	   factor	   activation	   (10).	  
A	   B	  
Figure	  1.1	  A)	  Structure	  of	  influenza	  virus	  depicting	  segmented	  viral	  genome	  and	  proteins.	  (modified	  from	  ref.	  6)	  B)	  Influenza	  replication	  pathway:	  binding	  to	  cell	  membrane,	  fusion	  and	  release	  of	  viral	  genome,	  protein	  synthesis,	  budding	  and	  release	  from	  cell	  membrane	  (modified	  from	  ref.	  7)	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There	  are	  also	  a	  variety	  of	  secreted,	  trypsin-­‐like	  proteases,	  such	  as	  tryptase	  and	  matriptase,	  which	  have	  been	  shown	  to	  cleave	  HA	  in	  vitro	  (11).	  	  This	   cleavage	   gives	   rise	   to	   a	   prefusion	   state	   HA,	   priming	   the	   fusion	   peptide	   for	  fusion	  with	  the	  host	  cell	  membrane	  (Figure	  1.2)	  (12).	  As	  the	  early	  endosome	  shifts	  to	  the	  late	   endosome	   and	   the	   pH	   drops,	   a	   conformational	   change	   occurs	   in	   the	   HA	   protein,	   as	  (Figure	   1.2)	   (12).	   The	   HA	   protein	   unfolds,	   relocating	   the	   fusion	   peptide	   so	   that	   it	   is	   no	  longer	  buried	  and	  can	  initiate	  fusion	  with	  the	  host	  cell	  membrane	  (5).	  A	   fusion	  pore	   is	   formed	  by	  the	  release	  of	   the	  segmented	  genome	  into	  the	  host	  cell	  (5).	  The	  genome	  is	  brought	  to	  the	  nucleus	  where	  it	  can	  use	  host	  cell	  mechanisms	  to	  create	  the	  mRNA	  necessary	  to	  start	  the	  new	  influenza	  virus	  (1).	  Once	  the	  viral	  ribo-­‐nucleoproteins	  (RNP)	   are	   exported	   out	   of	   the	   nucleus,	   they	   translocate	   and	   are	   assembled	   at	   the	   apical	  plasma	   membrane	   (1).	   M2	   plays	   a	   role	   in	   packaging	   the	   viral	   particles	   while	   M1	   is	  important	   in	   closing	   and	   budding	   off	   the	   newly	   formed	   influenza	   particle	   (1).	   Before	  budding	   from	   the	   host	   cell,	   NA	   must	   cleave	   off	   the	   sialic	   acid	   on	   the	   viral	   envelope,	  preventing	  aggregation	  of	  virus	  and	  allowing	  it	  to	  be	  released	  from	  the	  cell	  (1,	  14).	  
Influenza	  Prevention	  and	  Treatment	  	  	   The	   influenza	   vaccine	   is	   the	   most	   effective	   way	   to	   prevent	   influenza	   infection.	  Annual	  influenza	  vaccination	  is	  recommended	  for	  anyone	  above	  six	  months	  (15).	  The	  most	  widely	  used	  seasonal	  vaccine	  is	  the	  trivalent	  or	  quadrivalent	  inactivated	  vaccine	  (16).	  It	  is	  made	  up	  of	   three	  or	   four	  currently	  circulating	   influenza	  strains,	   two	  or	   three	   influenza	  A	  types	   and	   one	   influenza	   B	   type	   (16).	   The	   WHO	   coordinates	   global	   surveillance	   data	   to	  determine	   which	   three	   influenza	   types	   will	   be	   present	   in	   the	   current	   vaccine	   (17).	   The	  strains	  are	  picked	  relatively	  early	  compared	  to	  the	  influenza	  season,	  as	  it	  requires	  time	  to	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  manufacture	  the	  vaccine	  (16).	  If	  no	  matching	  strains	  are	  chosen	  for	  the	  prevalent	  influenza	  types	   during	   the	   influenza	   season,	   the	   vaccine	   loses	   its	   efficacy.	   Even	   when	   strains	   are	  matched	  well,	  the	  vaccines	  do	  not	  induce	  long-­‐lasting	  antibody	  titers,	  resulting	  in	  about	  a	  47%	  effectiveness	  rate	  (19).	  
Figure	  1.2	  (modified	  from	  ref.	  13)	  HA	  conformational	  change	  to	  induce	  fusion	  with	  host	  cell	  membrane.	  HA	  is	  cleaved	  at	  the	  cleavage	  loop	  by	  host	  cell	  proteases	  to	  release	  fusion	  peptide	  (yellow).	  A	  low	  pH	  induces	  a	  conformational	  change,	  extending	  the	  fusion	  peptide	  and	  allowing	  for	  fusion	  to	  occur.	  D)	  Variety	  of	  cleavage	  loop	  consensus	  sequences	  showing	  conserved	  cleavage	  site	  (modified	  from	  ref.	  18)	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   There	   are	   also	   a	   variety	   of	   antiviral	   drugs	   approved	   by	   the	   Food	   and	   Drug	  Administration	  (FDA)	  to	  treat	  influenza	  after	  it	  has	  been	  contracted.	  Antivirals	  decrease	  the	  time	  period	  of	   infection	  as	  well	  as	   lessen	  symptoms	   that	  occur	  because	  of	   infection	   (17).	  They	  are	  mainly	  effective	  if	  taken	  within	  48	  hours	  of	  infection	  (17).	  Originally,	  there	  were	  two	   classes	   of	   anti-­‐influenza	   drugs	   available,	   adamantanes	   and	   NA	   inhibitors	   (17).	   The	  adamantanes	  include	  the	  drugs	  amantadine	  and	  rimantadine	  and	  work	  by	  blocking	  the	  M2	  ion	   channel	   and	   interfering	   with	   the	   early	   stages	   of	   viral	   replication	   (17).	   Shortly	   after	  adamantanes	  were	  discovered,	  resistant	  influenza	  strains	  began	  to	  show	  up	  due	  to	  changes	  in	   the	  M2	   ion	  channel	   (20).	  NA	   inhibitors	   include	  oseltamivir	  and	  zanamvir	  and	  work	  by	  blocking	   exit	   of	   the	   virus	   from	   the	   infected	   host	   cell	   (17).	   Although	   oseltamivir	   and	  zanamvir	  are	  the	  current	  antivirals	  to	  treat	  influenza,	  there	  are	  increasingly	  more	  cases	  of	  influenza	  resistant	  strains	  (20).	  Because	  these	  drugs	  target	  viral	  proteins,	  they	  will	  always	  be	  susceptible	  to	  changes	  in	  the	  viral	  genome	  (20).	  	  More	   recently,	   researchers	   have	   begun	   to	   look	   at	   targeting	   host	   cell	   mechanisms	  that	   are	   used	   by	   the	   virus	   to	   replicate	   (21).	   Some	  methods	   currently	   being	   studied	   are	  removing	  the	  areas	  of	  sialidase	  that	  are	  recognized	  by	  influenza	  viruses	  as	  well	  as	  targeting	  host	  signaling	  pathways	  that	  play	  a	  role	  in	  influenza	  replication	  (21).	  Another	  way	  is	  to	  use	  protease	  inhibitors	  to	  limit	  HA	  cleavage	  (21).	  Recently,	  peptide-­‐mimetic	  protease	  inhibitors	  of	  HAT	  and	  TMPRSS2	  were	  shown	  to	  block	  viral	  replication	  in	  vitro	  through	  the	  inhibition	  of	   HA	   cleavage	   (22).	   Also,	   a	   serine	   protease	   inhibitor,	   aprotinin,	   has	   been	   studied	   as	   an	  anti-­‐influenza	  agent.	  (20)	  There	  are	  already	  a	  variety	  of	  aprotinin	  compounds	  licensed	  as	  drugs	   for	  post-­‐operative	  bleeding	  and	  pancreatitis	   (20).	  However,	   its	   characteristics	   as	   a	  serine	   protease	   inhibitor	   made	   it	   a	   good	   choice	   to	   inhibit	   proteases	   responsible	   for	   HA	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cleavage	  (20).	  It	  has	  been	  shown	  to	  reduce	  the	  symptoms	  of	  influenza	  by	  limiting	  infection	  (20).	  
Human	  Parainfluenza	  1	  Virus	  	   Human	  parainfluenza	   I	   virus	   (HPIV-­‐1)	   causes	   upper	   and	   lower	   respiratory	   illness	  that	   results	   in	   fever,	   runny	   nose,	   and	   cough	   (23)	   More	   serious	   symptoms	   are	   croup	  (swelling	  around	  the	  windpipe),	  bronchitis,	  and	  pneumonia	  (24).	  HPIVs	  are	  a	  leading	  cause	  of	   acute	   respiratory	   infections	   in	   children,	   with	   HPIV-­‐1	   causing	   about	   28,900	  hospitalizations	   annually	   (24).	   Transmission	   can	   occur	   through	   infectious	   fluids	   or	   the	  inhalation	   of	   airborne	   particles	   (23).	   These	   infections	   are	   often	   reoccurring	   and	   only	  controlled	   by	   disinfection	   of	   the	   environment	   (23).	   There	   are	   currently	   no	   vaccines	   or	  treatments	  for	  HPIV-­‐1	  (23).	  	  
Human	  Parainfluenza	  1	  Structure	  and	  Replication	  	   HPIV-­‐1	   is	  an	  enveloped,	  non-­‐segmented,	  negative	  sense	  single-­‐stranded	  RNA	  virus	  (25).	  There	  are	  six	  common	  structural	  proteins	  encoded	  in	  the	  genome	  (25).	  There	  are	  two	  surface	  proteins,	  hemagglutinin-­‐neuraminidase	  (HN)	  and	  the	   fusion	  protein	  (F)	  (25).	  The	  HN	  protein	  is	  important	  in	  viral	  entry	  while	  the	  F	  protein	  regulates	  the	  fusion	  of	  the	  virus	  envelope	  with	  the	  plasma	  membrane	  (26).	  The	  nucleoprotein	  (N),	  phosphoprotein	  (P),	  and	  large	   (L)	   proteins	   form	   the	   ribonucleoprotein	   complex	   to	   form	   its	   encapsulation	   (26).	  Finally,	   the	  matrix	   (M)	  protein	   is	   involved	   in	  budding	   from	   the	  plasma	  membrane	  of	   the	  infected	  cell	  (26).	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Figure	  1.3	  (modified	  from	  ref.	  26)	  A)	  Structure	  of	  a	  parainfluenza	  virus	  depicting	  unsegmented	  viral	  genome	  and	  viral	  proteins	  B)	  HPIV-­‐1	  replication	  pathway:	  binding	  to	  sialic	  acid,	  fusion	  with	  cell	  membrane	  and	  release	  of	  viral	  genome,	  protein	  synthesis,	  budding	  and	  release	  from	  cell	  membrane	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Similar	   to	   influenza,	   the	  HN	  protein	   binds	   to	   sialic	   acid	  when	   first	   infecting	   a	   cell	  (26).	  The	  HN	  protein	  must	  be	  present	  in	  order	  for	  fusion	  to	  occur	  (27).	  The	  F	  protein	  must	  then	  be	  cleaved	  by	  host	  cell	  proteases	  into	  two	  subunits	  so	  that	  the	  fusion	  peptide	  can	  be	  exposed	  and	  inserted	  into	  the	  target	  cell	  membrane	  (27).	  Then,	  the	  HPIV-­‐1	  nucleocapsid	  is	  released	   into	   the	  cytoplasm	  of	   the	  cell	   (25).	  Transcription	  occurs	  using	   the	  virus-­‐specific	  RNA-­‐dependent	  RNA	  polymerase	  while	  cellular	  mechanisms	  translate	  the	  viral	  mRNA	  into	  viral	   proteins	   (25).	   The	   matrix	   protein	   along	   with	   the	   N	   and	   P	   proteins	   form	   the	  nucleocapsid	  and	  then	  bud	  off	  the	  plasma	  membrane,	  releasing	  a	  newly	  formed	  virus	  (26).	  	  	  
Hepatocyte	  Growth	  Factor	  Activator	  Inhibitors	  	  Hepatocyte	  growth	  factor	  activators	  1	  and	  2	  (HAI-­‐1	  and	  HAI-­‐2	  respectively)	  are	  two	  broad	   range	   serine	  protease	   inhibitors	   belonging	   to	   the	  Kunitz	   family	   of	   serine	  protease	  inhibitors	   (28).	   Both	   are	   type	   1	   transmembrane	   glycoproteins	   that	   contain	   two	  extracellular	  Kunitz-­‐type	  domains	  and	  are	  closely	  related	  (28).	  The	  biological	  role	  of	  HAI-­‐1	  is	  thought	  to	  be	  as	  a	  potent	  inhibitor	  of	  hepatocyte	  growth	  factor	  activator	  (HGFA),	  a	  blood	  coagulant	  that	  converts	  hepatocyte	  growth	  factor	  into	  its	  active	  form	  (29).	  HAI-­‐1	  has	  also	  been	  found	  as	  a	  complex	  with	  matriptase	  in	  a	  variety	  of	  cells,	  as	  seen	  in	  Figure	  1.4	  (30).	  It	  is	  believed	   to	   regulate	   the	   activity	   of	   activated	  matriptase.	   Matriptase	   is	   a	   serine	   protease	  involved	   in	   a	   variety	   of	   proteases	   and	   has	   also	   been	   shown	   to	   have	   a	   significant	   role	   in	  tumor	  biology	  (31).	  HAI-­‐2	  is	  also	  present	  in	  many	  cells	  in	  association	  with	  matriptase	  and	  is	  believed	   to	   regulate	  prostasin-­‐dependent	  matriptase	  zymogen	  activation	   (32).	  Because	  of	   their	   roles	   in	   the	   regulation	  of	  matriptase,	  HAI-­‐1	  and	  HAI-­‐2	  have	  been	   investigated	  as	  tumor	  suppressants	  (33).	  As	  a	  broad	  range	  inhibitor,	  HAI-­‐1	  has	  also	  been	  shown	  to	  inhibit	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a	   variety	   of	   other	   proteases	   in	   the	   respiratory	   tract	   (33).	   The	   correlation	   between	  proteases	  that	  cleave	  and	  HA	  and	  those	  that	  are	  inhibited	  by	  HAI-­‐1	  or	  HAI-­‐2	  show	  shows	  promise	  in	  the	  use	  of	  HAI-­‐2	  as	  an	  antiviral	  therapeutic.	  	   	  
Figure	  1.4	  (modified	  from	  ref.	  30)	  Crystal	  structure	  of	  HAI-­‐1(yellow)	  bound	  to	  matriptase	  (green)	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Methods	  
HAI-­‐2	  Protein	  Purification	  	   The	  gene	  encoding	   for	   the	   ectodomain	  of	  mouse	  HAI-­‐2	   (MGC-­‐6479)	  was	  obtained	  from	  the	  mammalian	  gene	  collection	  and	  cloned	  into	  a	  modified	  pSUMO	  vector	  (provided	  by	   Holger	   Sondermann)	   and	   named	   HAI2-­‐pSUMO	   by	   Brian	   Hamilton.	   HAI2-­‐pSUMO	  was	  transformed	   into	   E.	   coli,	   RIL(DE3)	   (ArticExpress)	   by	   Brian	   Hamilton.	   The	   E.	   coli	   cells	  transformed	  with	  HAI2-­‐pSUMO	  were	   grown	   in	   50	  mL	   of	   Luria	   broth	   (LB)	   containing	   35	  μg/mL	  kanamycin	  at	  37°C	  overnight.	  Five	  mL	  of	  the	  culture	  was	  used	  to	  subculture	  a	  1	  liter	  culture	  of	  LB	  containing	  35	  μg/mL	  kanamycin.	  Once	  the	  culture	  reached	  an	  OD	  of	  0.5	  to	  0.8,	  it	  was	  induced	  with	  0.2M	  IPTG	  and	  incubated	  overnight	  at	  20°C.	  The	  cells	  were	  collected	  by	  centrifugation	   and	   resuspended	   in	   lysis	   buffer	   (50	   mM	   Tris,	   300	   mM	   NaCl,	   10	   mM	  imidazole,	  pH	  7.8).	  The	  cells	  were	  sonicated	  for	  4	  minutes	  at	  2	  seconds	  on	  and	  2	  seconds	  off	  and	  cell	  debris	  was	  removed	  by	  centrifugation.	  The	  bacterial	  lysate	  was	  filtered	  and	  loaded	  onto	   a	   7	   mL	   bed	   volume,	   Ni2+-­‐NTA	   agarose	   resin	   gravitational	   column	   that	   was	   pre-­‐equilibrated	  with	   five	   column	   volumes	   lysis	   buffer	   and	   subsequently	  washed	  with	   thirty	  column	  volumes	  wash	  buffer	  (25	  mM	  Tris,	  150	  mM	  NaCl,	  10	  mM	  imidazole,	  pH	  7.8).	  HAI-­‐2	  was	  eluted	  with	  two	  column	  volumes	  elution	  buffer	  (25	  mM	  Tris,	  150	  mM	  NaCl,	  200	  mM	  imidazole,	  pH	  7.8)	  and	  transferred	  to	  a	  15-­‐mL	  Falcon	  tube.	  The	  concentration	  of	  HAI-­‐2	  was	  determined	  by	  Nanodrop	  and	  thrombin	  was	  subsequently	  added	  to	  cleave	  off	  the	  His-­‐tag.	  The	   elution	   was	   incubated	   overnight	   at	   4°C.	   The	   eluted	   HAI-­‐2	   was	   then	   loaded	   onto	   a	  Superdex200	   size-­‐exclusion	   column	   equilibrated	  with	   GFP	   buffer	   (50	  mM	   Tris,	   150	  mM	  NaCl).	  It	  was	  run	  for	  90	  mL	  at	  0.4	  mL/min.	  The	  eluted	  peaks	  were	  tested	  for	  HAI-­‐2	  by	  SDS-­‐PAGE.	  	  For	  studies	  in	  mice,	  purified	  HAI-­‐2	  was	  treated	  to	  remove	  bacterial	  endotoxins	  using	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a	   1	  mL	  Detoxi-­‐Gel	   Endotoxin	  Removing	  Column	   from	  Thermo	  Scientific	   according	   to	   the	  manufacturer’s	  protocol.	  The	  protein	  concentration	  was	  then	  determined	  by	  Nanodrop.	  
HA	  peptide	  cleavage	  inhibition	  assay	  
	  	   Peptides	  were	  designed	  to	  mimic	  the	  consensus	  cleavage	  site	  region	  of	  the	  HA	  of	  the	  H1	   (IPSIQSRGLF)	   and	   H3	   (VPEKQTRGLF)	   subtypes.	   As	   a	   FRET	   pair,	   MCA	   (7-­‐methoxycoumarin-­‐4-­‐yl	   acetyl)	   was	   added	   to	   the	   N-­‐terminus,	   and	   DNP	   (N-­‐2,4-­‐dinitrophenyl)	   was	   added	   to	   the	   C-­‐terminus	   (RS	   Synthesis).	   HAI-­‐2,	   trypsin	   and	   each	  peptide	  were	  diluted	  in	  buffer	  B,	  producing	  a	  final	  concentration	  of	  0-­‐1	  µM	  HAI-­‐2,	  0.8	  nM	  trypsin,	   and	   100	   µM	   peptide.	   The	   reaction	   was	   immediately	   carried	   out	   at	   37°C	   and	  monitored	   for	   cleavage	   by	   the	   change	   in	   fluorescence	   at	   390	  nm	   (SpectraMax	  GeminiXS,	  Molecular	  Devices).	  The	  IC50	  value	  denotes	   the	  HAI-­‐2	  concentration	  at	  which	  trypsin	  was	  inhibited	  by	  50%,	   as	   compared	   to	   the	   uninhibited	   control.	   The	   initial	   rate	   at	   each	  HAI-­‐2	  concentration	   was	   both	   plotted	   and	   fitted	   using	   Origin	   software	   (OriginLab	   Corp.)	   to	  determine	  the	  IC50	  values.	  
HA	  cleavage	  inhibition	  by	  Western	  blot	  
293T	   cells	   were	   transfected	   with	   1	   µg	   of	   each	   HA-­‐expressing	   plasmid	   using	  Lipofectamine	  2000	   (Invitrogen)	   for	  12	  hours	  at	  37°C.	  Three	  µg/ml	   trypsin	  along	  with	  a	  concentration	  range	  of	  HAI-­‐2	  (0-­‐1	  µM)	  were	  pre-­‐incubated	  in	  buffer	  A	  for	  10	  min	  at	  37°C,	  the	   cells	   washed	   with	   phosphate	   buffered	   saline	   (PBS)	   and	   treated	   with	   each	   protease-­‐inhibitor	   mixture	   for	   45	   min	   at	   37°C.	   	   The	   cells	   were	   then	   processed	   by	   cell	   surface	  biotinylation	   in	   preparation	   for	   western	   blot	   analysis.	   	   Inhibition	   of	   HA	   cleavage	   was	  assessed	   by	   western	   blot	   using	   anti-­‐A/PR/8/34	   (H1)	   and	   anti-­‐A/Hong	   Kong/1/68	   (H3)	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antibodies	   (NIAID	   Biodefense	   &	   Emerging	   Infections	   Research	   Resource	   Repository).	  Western	  blot	  images	  were	  taken	  by	  FujiFilm	  LAS-­‐3000.	  The	  pixel	  intensity	  of	  the	  individual	  band	  was	  measured	  by	   Image	   J,	   and	   relative	   cleavage	  efficiencies	  were	   calculated	  by	   the	  following	  equation:	  (HA2/HA0+HA2)	  x100%.	  	  
Inhibition	  of	  influenza	  infection	  in	  cell	  culture	  
To	  measure	   infection	  of	   individual	   cells,	   non-­‐cleaved	  A/PR8/34	  was	  generated	  by	  incubation	  of	  1	  pfu/cell	  egg-­‐derived	  virus	  with	  293T	  cells	  in	  a	  6	  cm	  dish	  containing	  RPMI	  for	  1	  hr	  at	  37°C.	  	  293T	  cells	  were	  chosen	  due	  to	  their	  lack	  of	  endogenous	  proteases	  capable	  of	  cleaving	  HA.	   	  The	  non-­‐cleaved	  virus	  was	  incubated	  with	  the	  inhibitor-­‐protease	  mixture	  described	  above	  for	  20	  min	  at	  37°C.	  Cleavage	  of	  HA	  was	  terminated	  by	  the	  addition	  of	  5	  µg	  of	  trypsin	  inhibitor	  (EMD	  Chemicals).	  MDCK	  cells	  were	  grown	  in	  24-­‐well	  plates	  containing	  glass	  cover	  slips	  and	  infected	  with	  the	  virus	  at	  each	  HAI-­‐2	  concentration	  and	  incubated	  for	  5	   hr	   at	   37°C.	   The	   cells	  were	   fixed	  with	   4%	  paraformaldehyde,	   permeabilized	  with	   0.5%	  Triton	  X-­‐100,	  washed	  with	  PBS	  and	  assessed	  for	  infection	  by	  immunofluorescence	  using	  a	  polyclonal	  anti-­‐nucleoprotein	  antibody	  coupled	  followed	  by	  an	  Alexa	  Fluor	  488-­‐conjugated	  anti-­‐rabbit	  secondary	  antibody.	  The	  cell	  nuclei	  were	  stained	  with	  Hoechst	  33258	  or	  DAPI.	  Cells	  were	  images	  on	  a	  Nikon	  E600	  epifluorescence	  microscope	  using	  a	  20X	  objective.	  
To	   measure	   virus	   replication	   and	   spread,	   egg-­‐derived	   influenza	   A/PR8/34	  (containing	   cleaved	  HA)	  was	   used	   to	   infect	  MDCK	   cells	   at	   a	   low	  multiplicity	   of	   infection	  (approximately	  0.01	  pfu/cell)	  in	  24-­‐well	  plates.	  Trypsin	  was	  included	  in	  the	  media	  to	  allow	  virus	  spread,	  and	  samples	  were	  treated	  with	  each	  HAI-­‐2	  concentration,	  or	  were	  untreated.	  Media	  was	  collected	  at	  48	  hr,	  remaining	  trypsin	  activity	  was	  blocked	  by	  the	  addition	  of	  5	  µg	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of	   trypsin	   inhibitor,	  and	  supernatant	  containing	  virus	  was	  transferred	  to	  a	  96-­‐well	  plates	  for	  virus	  quantification	  by	  hemagglutination	  assay.	  	  
HAI-­‐2	  Effect	  on	  VSV	  MDCK	  cells	  were	   infected	  with	  vesicular	   stomatitis	  virus	   (VSV)	   in	   the	  presence	  or	  absence	   of	   HAI-­‐2	   and	   1	   μg/mL	   trypsin	   for	   five	   hours.	   The	   concentrations	   of	   HAI-­‐2	   used	  were:	   10	   nM,	   50,	   Nm,	   150	   nM,	   5000	   nM,	   or	   1000	   nM.	   Infection	  was	   then	  monitored	   by	  immunofluorescence	   microscopy.	   The	   cells	   were	   fixed	   with	   4%	   PFA	   and	   permeabilized	  with	   0.5%	   Triton	   in	   PBS.	   The	   cells	   were	   blocked	   with	   10%	   FBS	   in	   PBS.	   The	   primary	  antibody	   used	   was	   mouse	   anti-­‐VSV	   glycoprotein	   (AbCam)	   at	   a	   1:500	   dilution.	   The	  secondary	  antibody	  used	  was	  anti-­‐mouse	  Alexafluor488	  (Invitrogen)	  at	  a	  1:1000	  dilution.	  The	   nuclei	   were	   stained	   with	   DAPI.	   Images	   were	   taken	   with	   a	   Nikon	   Eclipse	   e600	  microscope	  using	  a	  20x	  objective.	  
Inhibition	  of	  HPIV-­‐1	  infection	  in	  cell	  culture	  	   LLC-­‐MK2	  cells	  were	  infected	  with	  HPIV-­‐1	  at	  low	  multiplicity	  of	  infection.	  The	  virus	  was	   incubated	   for	  one	  week	  at	  37°C	   in	   the	  presence	  of	  1	  μg/mL	  exogenous	   trypsin.	  Cells	  were	   treated	  with	  a	   range	  of	  HAI-­‐2	  concentrations:	  10	  nM,	  50	  nM,	  150	  nM,	  500	  nM,	  and	  1000	  nM.	  Trypsin	  was	  added	  every	  48	  hours	  to	  replenish	  the	  supply.	  After	  seven	  days,	  the	  cells	  were	   fixed	  with	  4%	  PFA	   and	  permeabilized	  with	  0.5%	  Triton.	   Immunofluorescence	  microscopy	  was	  used	  to	  look	  at	  spread	  of	  infection	  using	  a	  Nikon	  Eclipse	  microscope	  using	  a	   20x	   objective.	  Mouse	   anti-­‐parainfluenza	   virus	   type	   1	   antibody	   conjugated	   to	   FITC	  was	  used	  to	  visualize	  the	  infection.	  The	  nuclei	  were	  stained	  with	  DAPI.	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HAI-­‐2	  Toxicity	  Test	  Eight-­‐week-­‐old	  balb-­‐c	  mice	  were	  administered	  varying	  concentrations	  of	  HAI-­‐2	  or	  PBS.	  There	  were	  four	  groups	  of	  mice,	  each	  with	  three	  mice	  in	  each	  group.	  Each	  group	  was	  administered	   0.5	   mg/kg,	   0.75	   mg/kg,	   2.5	   mg/kg	   HAI-­‐2	   or	   PBS	   only.	   The	   doses	   were	  administered	   intranasally	   under	   anesthesia	   (isoflurane).	   Each	   group	   was	   housed	   in	   a	  different	  cage	  depending	  on	  treatment.	  The	  mice	  were	  given	  50	  μL	  doses	  of	  PBS	  or	  HAI-­‐2	  every	  12	  hr	  for	  three	  days.	  The	  mice	  were	  monitored	  twice	  daily	  for	  weight	  loss.	  	  
Influenza	  PR8	  Lethality	  Test	  	   Eight-­‐week	   old	   balb-­‐c	   mice	   were	   infected	   with	   mouse-­‐adapted	   influenza,	  A/PR/8/34	  (PR8)	  ranging	  from	  1	  foci	  fluorescent	  unit	  (ffu)	  to	  1000	  ffu	  or	  PBS.	  There	  were	  six	   groups	  of	  mice	  with	   three	  mice	   in	   each	   group.	  The	  mice	  were	   infected	   via	   intranasal	  administration	  under	  anesthesia	  (isoflurane)	  with	  the	  varying	  concentrations	  diluted	  in	  50	  μL	  PBS.	  Each	  group	  was	  housed	  in	  a	  different	  cage	  depending	  on	  their	  infection	  dose.	  The	  mice	   were	   infected	   on	   Day	   1	   and	   their	   weight	   was	   monitored	   daily	   over	   the	   course	   of	  twelve	   days.	   Animals	   showing	  weight	   loss	   greater	   than	   20%	  of	   their	   initial	  weight	  were	  euthanized.	  
PR8	  HAI-­‐2	  Challenge	  8-­‐week-­‐old	  female	  balb-­‐c	  mice	  were	  inoculated	  under	  mild	  anesthesia	  (isoflurane).	  The	   inoculums	   were	   administered	   intranasally,	   with	   half	   of	   total	   volume	   per	   nostril.	  Treatment	  was	  performed	  at	  time	  0	  with	  0.75	  mg/kg	  HAI-­‐2	  diluted	  in	  50	  μL	  PBS.	  After	  four	  hours,	  infection	  was	  performed	  with	  a	  50	  μL	  solution	  containing	  100	  ffu	  of	  influenza	  virus	  (A/PR/8/34).	   Subsequent	   HAI-­‐2	   administrations	   were	   performed	   at	   12-­‐hour	   intervals	  during	  the	  course	  of	  five	  days.	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   The	  experiment	  was	  performed	  with	  five	  mice	  in	  each	  group,	  with	  animals	  housed	  in	  different	  cages	  depending	  on	  treatment.	  The	  four	  groups	  were	  as	  follows:	  1)	  PBS	  only	  2)	  HAI-­‐2	  only	  3)	  PR8	  only	  4)	  HAI-­‐2/PR8.	  Mice	  were	  monitored	  twice	  daily	   for	  clinical	  signs,	  such	  as	  scruffiness	  and	  body	  weight	  loss.	  Animals	  showing	  weight	  loss	  higher	  than	  30%	  of	  initial	  weight	  were	  euthanized.	  Lung	  tissue	  was	  removed	  post-­‐mortem	  and	  utilized	  for	  viral	  titer	  determination	  by	  foci	  fluorescent	  assay.	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Results	  
HAI-­‐2	  Protein	  Purification	  	   HAI-­‐2	  was	  first	  purified	  by	  a	  Ni2+	  agarose	  column	  since	  the	  HAI-­‐2	  protein	  had	  been	  designed	  with	  a	  His-­‐tag	  attached	  to	  it.	  However,	  as	  can	  be	  seen	  in	  Lane	  5,	  there	  are	  still	  a	  variety	   of	   other	   bands	   present	   after	   this	   purification	   process	   (Figure	   4.1).	   The	   size	  exclusion	   column	  was	   then	  used	   to	   eliminate	   these	   other	   bands	   as	  well	   as	   the	   thrombin	  that	   was	   used	   to	   cleave	   the	   His-­‐tag.	   Two	   peaks	   were	   present	   in	   the	   fast	   protein	   liquid	  chromatography	   (FPLC)	   trace.	   As	   can	   be	   seen	   in	   Lane	   6,	   the	   first	   peak	   contained	   the	  purified	  HAI-­‐2	  at	  21	  kDa.	  However,	  it	  was	  still	  not	  completely	  purified,	  as	  two	  other	  bands	  were	  also	  present.	  The	   lower	  band	  could	  be	  degraded	  HAI-­‐2.	  Both	  bands	  could	  also	  be	  a	  result	   of	   nonspecific	   binding.	   In	   the	   second	   peak,	   there	   was	   a	   band	   at	   about	   75	   kDa,	  showing	  the	  thrombin	  was	  effectively	  removed	  from	  the	  HAI-­‐2	  sample.	  HAI-­‐2	  was	  purified	  from	  the	  E.	  coli	  resulting	  in	  a	  yield	  of	  0.4	  mg/L.	  In	  order	  to	  further	  purify	  the	  sample	  in	  the	  future,	   the	   purified	   HAI-­‐2	   could	   be	   run	   through	   the	   Ni2+	   agarose	   column,	   allowing	   the	  cleaved	  HAI-­‐2	  to	  elute	  while	  allowing	  for	  anything	  nonspecific	  to	  bind	  to	  the	  column.	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100	  kDa	  -­‐-­‐	  70	  kDa	  -­‐-­‐	  
35	  kDa	  -­‐-­‐	  25	  kDa	  -­‐-­‐	  15	  kDa	  -­‐-­‐	  10	  kDa	  -­‐-­‐	  
Lane	  1:	  Ladder	  Lane	  2:	  Insoluble	  cell	  pellet	  Lane	  3:	  Flow	  through	  Lane	  4:	  Wash	  Lane	  5:	  Ni2+	  Column	  Elution	  after	  thrombin	  Lane	  6:	  FPLC	  Peak	  1	  Lane	  7:	  FPLC	  Peak	  2	  
Figure	  4.1	  SDS-­‐PAGE	  gel	  depicting	  different	  stages	  of	  HAI-­‐2	  purification	  process,	  as	  labeled	  by	  key.	  Purified	  HAI-­‐2	  (red	  arrow)	  and	  removed	  thrombin	  (blue	  arrow)	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In	  Vitro	  HAI-­‐2	  Characterization	  
HAI-­‐2-­‐mediated	  inhibition	  of	  peptide	  mimics	  of	  H1N1	  and	  H3N2	  influenza	  	  
Inhibition	  of	  peptide	  mimics	  of	  the	  HA	  cleavage	  site	  by	  HAI-­‐2	  was	  first	  investigated,	  using	  the	  established	  activity	  of	  trypsin	  as	  a	  surrogate	  of	  in	  vivo	  trypsin-­‐like	  proteases	  (34).	  HAI-­‐2	   activity	   was	   competed	   with	   HA	   cleavage	   site	   peptide	  mimics	   of	   both	   the	   human-­‐adapted	   H1	   and	   H3	   subtypes	   (A/PR/8/34	   and	   A/Aichi/2/68	   respectively).	   The	   peptide	  sequences	   were	   designed	   based	   on	   the	   consensus	   amino	   acid	   sequence	   of	   cleavage	   site	  region	  of	  each	  subtype.	  Competition	  of	  HAI-­‐2	  and	  each	  peptide	  with	  trypsin	  resulted	  in	  an	  IC50	   value	  of	  22.4+/-­‐10nM	   for	   the	  H1	  peptide	  mimic	   and	  89.9+/-­‐6nM	   for	   the	  H3	  peptide	  mimic	  (Fig.	  4.2	  A	  and	  B).	  While	  HAI-­‐2	  was	  slightly	  more	  active	  against	  cleavage	  of	  the	  H1	  subtype	   peptide	  mimic,	   potent	   inhibition	  was	   observed	   against	   both	   peptide	   substrates.	  Work	  done	  by	  Brian	  Hamilton.	  
	   	  
Figure	  4.2	  Graphs	  of	  HAI-­‐2	  inhibition	  of	  trypsin	  cleavage	  of	  A)	  the	  H1	  subtype	  cleavage	  site	  peptide	  mimic	  and	  B)	  the	  H3	  subtype	  cleavage	  site	  peptide	  mimic.	  Peptide	  sequences	  indicated	  in	  titles	  of	  respective	  graphs.	  Experiment	  performed	  by	  Brian	  Hamilton.	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Inhibition	  by	  HAI-­‐2	  of	  influenza	  H1N1	  and	  H3N2	  HA	  cleavage	  	   To	  determine	  whether	  HAI-­‐2	  has	   the	   ability	   to	   inhibit	  HA	   cleavage	   in	   cell	   culture,	  HAI-­‐2	   at	   a	   concentration	   range	   of	   0-­‐1	  µM	  was	   incubated	  with	   trypsin,	   and	   subsequently	  incubated	  with	  HA-­‐expressing	  cells.	  Inhibition	  of	  HA	  cleavage	  was	  assessed	  by	  western	  blot	  analysis,	  where	  HA2	  bands	  are	  not	  detected	  well	  with	  the	  anti-­‐sera	  used,	  which	  is	  selective	  for	  the	  HA1	  subunit.	  Effective	  inhibition	  of	  HA	  cleavage	  was	  observed	  for	  both	  the	  H1	  and	  H3	   subtypes	   (A/PR/8/34	   and	   A/Aichi/2/68	   respectively),	   where	   cleavage	   was	   virtually	  abolished	  at	  an	  HAI-­‐2	  concentration	  of	  150	  nM,	  and	  greatly	  reduced	  at	  50	  nM	  HAI-­‐2	  (Fig.	  4.3	   A	   and	   B).	   	   Thus,	   cleavage	   of	   the	   HA	   from	   both	   of	   the	   currently	   circulating	   human-­‐adapted	  subtypes	  is	  potently	  inhibited	  by	  HAI-­‐2.	  Work	  done	  by	  Brian	  Hamilton. 
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Figure	  3.3	  A)	  Western	  blot	  analysis	  of	  HAI-­‐2	  inhibition	  of	  H1N1	  HA	  and	  H3N2	  HA	  cleavage	  by	  trypsin	  B)	  Quantification	  of	  the	  percent	  HA	  cleavage	  from	  A)	  using	  densitometry.	  Experiment	  performed	  by	  Brian	  Hamilton	  
H1N1 
H3N2 
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Inhibition	  of	  influenza	  virus	  infection	  by	  HAI-­‐2	  	  
As	   an	   additional	  measure	   of	   inhibition	   in	   cell	   culture,	  HAI-­‐2	   activity	   on	   infectious	  virus	  particles	  was	  determined,	  both	  directly	  at	   the	   level	  of	  virus	  entry,	   as	  well	   as	  at	   the	  level	   of	   virus	   spread.	   To	   examine	   virus	   entry	   directly,	   non-­‐cleaved,	   inactive	   influenza	  A/PR/8/34	  (H1N1)	  was	  generated	  by	  a	  single	  round	  of	  replication	  in	  mammalian	  cells	  that	  are	  incapable	  of	  cleaving	  HA.	  Inhibition	  of	  viral	  activation	  was	  assessed	  by	  treatment	  of	  the	  virus	  with	   trypsin	  and	  various	  concentrations	  of	  HAI-­‐2,	   followed	  by	   immunofluorescence	  staining	   of	   the	   viral	   nucleoprotein	   in	   infected	   cells.	   Similar	   to	   inhibition	   of	   HA	   cleavage	  observed	  by	  western	  blot	  analysis,	  effective	  inhibition	  of	  infection	  of	  influenza	  A/PR/8/34	  infection	  was	  observed	  by	  treatment	  with	  HAI-­‐2	  (Fig.	  4.4	  A).	  Work	  done	  by	  Brian	  Hamilton.	  
To	   examine	   the	   effects	   of	   HAI-­‐2	   on	   influenza	   virus	   propagation	   and	   spread,	  influenza	  A/PR/8/34	  (H1N1)	  was	  produced	  in	  embryonated	  chicken	  eggs,	  yielding	  virions	  with	   cleaved	   and	   active	   HA.	   These	   viruses	   were	   used	   to	   infect	   MDCK	   cells	   at	   a	   low	  multiplicity	  of	   infection,	  and	  cells	  were	  incubated	  for	  48	  hr	  to	  allow	  virus	  replication	  and	  spread.	  The	  TCID50	  was	  attempted,	  but	   infected	  cells	  were	  difficult	   to	  discern.	  Media	  was	  then	   harvested	   and	   virus	   was	   quantified	   by	   hemagglutination	   assay	   (Fig.	   4.4	   B).	   Potent	  inhibition	  of	  influenza	  A/PR/8/34	  infection,	  in	  a	  dose-­‐dependent	  manner,	  was	  observed	  by	  treatment	  with	  HAI-­‐2.	  Overall,	  HAI-­‐2	  effectively	   inhibited	   influenza	  virus	   infection	   in	   cell	  culture.	  Work	  done	  by	  Yoko	  Yoda.	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Figure	  4.4	  A)	  Immunofluorescence	  staining	  of	  the	  viral	  nucleoprotein	  (NP)	  of	  infected	  cells	  after	  trypsin	  treatment	  with	  500	  nM	  HAI-­‐2,	  and	  no	  protease	  treatment	  (mock).	  The	  viral	  NP	  was	  labeled	  with	  Alexa	  fluor	  488	  (green)	  and	  the	  nucleus	  was	  stained	  with	  DAPI	  (blue).	  B)	  MDCK	  cells	  were	  infected	  with	  a	  low	  MOI	  of	  influenza	  virus,	  and	  infection	  was	  allowed	  to	  spread	  for	  48h	  in	  the	  presence	  of	  representative	  amounts	  of	  HAI-­‐2.	  Virus	  yield	  was	  measured	  by	  hemagglutination	  (HA)	  assay	  in	  triplicate,	  and	  individual	  HA	  units	  (HAU)	  in	  each	  condition	  plotted.	  Experiments	  performed	  by	  Brian	  Hamilton	  and	  Yoko	  Yoda.	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Effects	  of	  HAI-­‐2	  on	  other	  enveloped	  viruses	  	   As	  a	  control,	  we	  assessed	  the	  effect	  of	  HAI-­‐2	  on	  the	  entry	  of	  an	  unrelated	  virus	  (VSV)	  that	  contained	  a	  glycoprotein	  (G)	  that	   is	  not	  activated	  by	  proteolytic	  cleavage	  (35).	  An	   incubation	  period	  of	   5	   hours	   allows	   enough	   time	   for	  VSV	   to	   infect	   cells,	   but	   not	   long	  enough	  for	  it	  to	  replicate	  and	  spread.	  As	  the	  concentration	  of	  HAI-­‐2	  increases,	  VSV	  still	  has	  the	  ability	  to	  infect	  cells	  (Figure	  4.5	  A).	  We	  also	  assessed	  the	  effect	  of	  HAI-­‐2	  on	  the	  entry	  of	  a	  related	  virus	  (HPIV-­‐1)	  that	  contained	  a	  fusion	  protein	  that	  is	  believed	  to	  be	  activated	  by	  similar	   proteases	   to	   influenza	  HA.	  As	  with	   influenza	   infection,	  HAI-­‐2	   treatment	   inhibited	  HPIV-­‐1	  infection	  in	  a	  dose-­‐dependent	  manner	  (Figure	  4.5	  B).	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Figure	  3.5	  A)	  Immunofluorescence	  staining	  of	  the	  VSV	  glycoprotein	  (G)	  in	  infected	  cells	  after	  trypsin	  treatment	  with	  representative	  amounts	  of	  HAI-­‐2,	  and	  no	  protease	  treatment	  (mock).	  The	  viral	  G	  protein	  was	  labeled	  with	  Alexa	  fluor	  488	  (green)	  and	  the	  nucleus	  was	  stained	  with	  DAPI	  (blue).	  B)	  Immunofluorescence	  staining	  of	  the	  HPIV-­‐1-­‐infected	  cells	  after	  trypsin	  treatment	  with	  representative	  amounts	  of	  HAI-­‐2,	  and	  no	  protease	  treatment	  (mock).	  HPIV-­‐1	  is	  labeled	  with	  FITC	  (green)	  and	  the	  nucleus	  was	  stained	  with	  DAPI	  (blue).	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In	  Vivo	  Characterization	  of	  HAI-­‐2	  using	  a	  Mouse	  Model	  	  
HAI-­‐2	  Toxicity	  Text	  	   To	   first	   examine	   any	   potential	   toxicology	   problems	  with	  HAI-­‐2,	   balb/c	  mice	  were	  exposed	   intranasally	   to	   HAI2	   at	   doses	   of	   2.5	   mg/kg,	   0.75	   mg/kg,	   and	   0.5	   mg/kg.	   Body	  weight	  and	  clinical	  signs	  were	  monitored	  for	  4	  days	  and	  mice	  were	  then	  euthanized.	  PBS	  was	   used	   as	   a	   control	   to	   ensure	   delivery	   methods	   were	   not	   harmful	   to	   the	   mice.	   The	  administration	  of	  HAI-­‐2	  at	  different	  doses	  did	  not	  harm	  the	  mice,	  as	  no	  significant	  weight	  loss	  or	  clinical	  signs	  were	  shown	  (Figure	  4.6).	  	  	   	  
Figure	  4.6	  Graph	  depicting	  average	  percent	  of	  original	  weight	  loss	  from	  each	  group	  of	  mice	  vs.	  days	  of	  experiment.	  Mice	  were	  treated	  with	  0.5	  mg/kg,	  0.75	  mg/kg,	  or	  2.5	  mg/kg	  HAI-­‐2	  or	  PBS	  intranasally.	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Figure	  4.7	  Graph	  depicting	  average	  percent	  of	  original	  weight	  loss	  from	  each	  group	  of	  mice	  vs.	  days	  of	  experiment.	  Mice	  were	  treated	  with	  varying	  doses	  of	  A/PR/8/34.	  
	   28	  
	  
Inhibition	  of	  influenza	  virus	  infection	  by	  HAI-­‐2	  in	  a	  mouse	  model	  	  	   There	   are	   two	  major	  ways	  mice	   display	   symptoms	  when	   infected	  with	   influenza:	  weight	  loss	  and	  survival.	  Both	  of	  these	  symptoms	  were	  monitored	  during	  the	  course	  of	  the	  experiment.	  To	  determine	  the	   inhibition	  effects	  of	  HAI-­‐2	  against	   influenza	   infection,	  mice	  were	  given	  an	  initial	  dose	  of	  0.75	  mg/kg	  HAI-­‐2	  and	  then	  challenged	  by	  100	  ffu	  A/PR/8/34	  intranasally.	  HAI-­‐2	  was	  administered	  intranasally	  every	  12	  hours	  through	  the	  course	  of	  the	  experiment.	  Mice	  were	  weighed	  and	  monitored	   twice	  daily	   for	  5	  days.	  Mice	   treated	  with	  HAI-­‐2	  as	  well	  as	  those	  only	   infected	  with	   influenza	   lost	  similar	  amounts	  of	  weight	  during	  the	  experiment	  (Figure	  3.8	  A).	  Although	  there	  was	  a	  slight	  delay	  in	  weight	  loss	  by	  the	  HAI-­‐2	  treated	  mice,	   there	  was	  no	  significant	  difference	   in	  the	  amount	  of	  weight	   lost	   in	  the	  mice	  treated	  with	  HAI-­‐2	  (unpaired	  p-­‐test,	  p	  value	  =	  0.5932).	  	  When	  determining	  survival,	  mice	  that	  had	  spontaneously	  died	  during	  the	  course	  of	  the	   experiment	  were	   plotted	   on	   a	   survival	   graph	   (Figure	   3.8	  B).	   Spontaneous	   death	  was	  defined	   by	   mice	   that	   were	   not	   euthanized	   but	   rather,	   were	   found	   dead	   while	   being	  monitored.	   On	   the	   fourth	   day,	   one	   influenza-­‐only	   mouse	   was	   found	   dead,	   while	   on	   the	  second	  day	   two	  more	   influenza-­‐only	  mice	  were	   found	  dead	   and	  one	  mouse	   treated	  with	  HAI-­‐2	  was	   found	   dead.	   Although	   the	   slight	   delay	   is	   still	   present	  when	   looking	   at	  mouse	  survival,	  there	  was	  no	  significant	  difference	  (Mandel-­‐Cox,	  p	  value	  =	  0.5439).	  	  Post-­‐experiment,	  mouse	  lungs	  were	  harvested	  to	  determine	  viral	  titer	  present	  in	  the	  lung	   tissue.	   Mice	   infected	   with	   influenza	   had	   an	   8.3	   x	   102	   ffu/g	   viral	   titer	   while	   those	  treated	  with	  HAI-­‐2	  had	  a	  7.0	  x	  102	  ffu/g	  viral	  titer.	  There	  was	  a	  significant	  decrease	  in	  the	  viral	  titer	  of	  the	  mice	  treated	  with	  HAI-­‐2	  (unpaired	  t-­‐test,	  p	  value	  =	  0.0001).	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Figure	  3.8	  A)	  Graph	  depicting	  average	  percent	  of	  original	  weight	  loss	  from	  each	  group	  of	  mice	  vs.	  days	  of	  experiment.	  Mice	  were	  given	  an	  initial	  treatment	  of	  HAI-­‐2	  and	  then	  challenged	  with	  A/PR/8/34.	  HAI-­‐2	  treatment	  was	  then	  given	  every	  12	  hours.	  B)	  Survival	  of	  mice	  during	  experiment.	  	  
A 
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Discussion	  Despite	  availability	  of	  vaccination	  and	  antiviral	  therapeutics,	  influenza	  still	  remains	  a	   significant	   concern	   for	   public	   health.	   New	   approaches	   to	   treating	   influenza	   need	   to	   be	  explored	   to	   combat	   newly	   emerging	   drug-­‐resistant	   influenza	   strains.	   Targeting	   host	  functions	  rather	  than	  viral	  proteins	  may	  be	  more	  effective,	  due	  to	  the	  decreased	  likelihood	  for	   the	   emergence	   of	   resistant	   influenza	   strains.	   The	   serine	   protease	   inhibitor,	   HAI-­‐2,	   is	  highly	   attractive	   anti-­‐influenza	   candidate	   due	   to	   the	   high	   correlation	   between	   the	  proteases	   that	   HAI-­‐2	   inhibits	   and	   the	   proteases	   shown	   to	   activate	   HA.	   We	   therefore	  investigated	   whether	   HAI-­‐2	   has	   the	   ability	   to	   inhibit	   HA	   cleavage,	   using	   trypsin	   as	   an	  established	  model	  protease	  for	  influenza	  infection	  in	  cell	  culture.	  HAI-­‐2	   was	   successfully	   purified	   for	   use	   in	   experiments	   with	   a	   yield	   of	   0.4	  mg/L.	  Despite	   the	   nonspecific	   bands	   present,	   HAI-­‐2	   showed	   activity	   in	   vitro	  and	   in	   vivo.	   HAI-­‐2	  showed	  potent	  inhibition	  of	  trypsin	  cleavage	  in	  vitro,	  as	  determined	  by	  the	  nM	  IC50	  values.	  HAI-­‐2	  was	  also	  able	  to	  inhibit	  infection	  and	  spread	  of	  both	  A/PR/8/34	  and	  HPIV-­‐1	  in	  cell	  culture	  starting	  at	  500	  nM	  concentration.	  Furthermore,	  HAI-­‐2	  did	  not	  affect	  infection	  of	  an	  unrelated	  virus	  (VSV).	  This	  shows	  that	  a	  high	  concentration	  of	  HAI-­‐2	  does	  not	   inhibit	  the	  ability	   for	  unrelated	  viruses	   to	  enter	   the	  cell,	  but	   is	   specific	   towards	  viruses	   that	   require	  trypsin	  or	  trypsin-­‐like	  proteases	  to	  infect	  host	  cells.	  An	   influenza	   mouse	   model	   was	   already	   established	   in	   the	   lab,	   allowing	   for	   the	  effects	  of	  HAI-­‐2	   inhibition	  of	   influenza	   to	  be	   looked	  at	   in	  vivo.	   The	   two	  major	  ways	  mice	  display	   symptoms	   when	   infected	   with	   influenza	   are	   weight	   loss	   and	   survival.	   HAI-­‐2	  treatment	  delivered	  intranasally	  showed	  no	  toxicity	  when	  delivered	  to	  mice.	  Determining	  the	  A/PR/8/34	  viral	  titer	  to	  use	  showed	  that	  this	  mouse-­‐adapted	  influenza	  is	  very	  effective	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against	  mice.	  Even	  a	   low	  100	  ffu	  dose	  was	  enough	  to	  be	  a	   lethal	  dose.	  Mice	   infected	  with	  A/PR/8/34	   and	   treated	   with	   HAI-­‐2	   showed	   no	   significant	   difference	   in	   weight	   loss	   or	  survival.	  Mice	   treated	  with	  HAI-­‐2	  may	  not	   have	   shown	   a	   significant	   difference	   in	  weight	  loss	   or	   survival	   because	   there	   was	   still	   a	   high	   enough	   A/PR/8/34	   viral	   titer	   to	   stop	  recovery	   from	   occurring.	   However,	   viral	   titer	   from	   lung	   tissue	   showed	   a	   significant	  decrease	   in	   the	  mice	   treated	  with	  HAI-­‐2,	   showing	   that	  HAI-­‐2	   can	   act	   on	   the	   trypsin-­‐like	  proteases	   present	   in	   the	   respiratory	   tract	   in	   vivo.	  Thus,	   HAI-­‐2	   has	   the	   potential	   to	   be	   a	  viable	  treatment	  to	  circumvent	  influenza	  infection.	  Although	  a	  comprehensive	  evaluation	  of	  the	  toxicity	  and	  effects	  of	  HAI-­‐2	  in	  experimental	  models	  more	  relevant	  to	  humans	  has	  not	  been	   done	   yet,	   our	   findings	   suggest	   it	   can	   be	   a	   viable	   candidate	   for	   further	   drug	  development.	  The	  inhibition	  of	  HPIV-­‐1	  by	  HAI-­‐2	  also	  suggests	  that	  it	  can	  target	  additional	  respiratory	  viruses	  with	  similar	  entry	  mechanisms	  to	  influenza.	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Conclusion	  	   Current	  influenza	  treatments	  are	  quickly	  becoming	  outdated	  as	  more	  influenza	  strains	   become	   resistant	   to	   them.	   A	   new	   method	   for	   treating	   influenza	   needs	   to	   be	  researched	   that	   does	   not	   focus	   on	   targeting	   influenza	   proteins,	   so	   as	   to	   circumvent	   the	  changing	   viral	   genome.	   The	   protease	   inhibitor,	   HAI-­‐2,	   is	   a	   promising	   agent	   to	   use	   as	   an	  antiviral	  to	  inhibit	  host	  proteases	  and	  prevent	  entry	  of	  influenza	  and	  other	  similar	  viruses	  into	  host	  cells.	  Here,	  we	  successfully	  purified	  HAI-­‐2	  for	  use	  in	  experiments.	  We	  showed	  that	  HAI-­‐2	  does	  not	  have	  any	  adverse	  effects	  on	  cells,	  even	  at	  high	  concentrations.	  HAI-­‐2	  is	  able	  to	   inhibit	   HA	   cleavage	   by	   trypsin	   in	   cells.	   HAI-­‐2	   was	   also	   able	   to	   inhibit	   the	   spread	   of	  influenza	  as	  well	  as	  HPIV-­‐1	  in	  vitro.	  Mice	  infected	  with	  PR8	  and	  treated	  with	  HAI-­‐2	  showed	  a	  very	  modest	  delay	  in	  weight	  loss	  and	  death.	  HAI-­‐2	  was	  likely	  able	  to	  inhibit	  host	  mouse	  proteases	  and	  decrease	  the	  replication	  of	  PR8	  in	  the	  mice,	  as	  shown	  by	  the	  viral	  titers	  from	  lung	  tissue.	  HAI-­‐2	  seems	  to	  be	  a	  promising	  candidate	  for	  an	  antiviral	  to	  treat	  influenza	  and	  other	  viruses	  with	  similar	  entry	  mechanisms.	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Future	  Directions	  
	   There	   are	   several	   areas	   to	   investigate	   for	   future	   studies	   involving	   HAI-­‐2.	   It	   was	  shown	  that	  HAI-­‐2	  decreased	  the	  viral	   titer	   in	  mouse	   lungs,	  but	   little	  recovery	  was	  shown	  while	   the	   mice	   were	   alive.	   By	   utilizing	   a	   lower	   viral	   titer	   of	   A/PR/8/34	   and	   a	   higher	  concentration	  of	  HAI-­‐2,	   treated	  mice	   could	   show	   less	  weight	   loss.	  Also,	   by	  delivering	   the	  HAI-­‐2	   treatment	   by	   an	   aerosol	   method,	   rather	   than	   intranasally,	   the	   amount	   of	   HAI-­‐2	  reaching	   the	   lungs	   can	   be	  more	   controlled.	   Since	  mice	   have	   few	   symptoms	   of	   influenza	  infection,	   further	   studies	   can	   use	   ferrets	   as	   a	   model	   organism.	   Ferrets	   have	   similar	  symptoms	   to	   humans	   and	   HAI-­‐2	   can	   be	   explored	   in	   a	   greater	   context.	   The	   inhibition	   of	  HPIV-­‐1	  by	  HAI-­‐2	  suggests	  HAI-­‐2	  has	  the	  ability	  to	   inhibit	  a	  variety	  of	  respiratory	  viruses.	  Other	  viruses,	  such	  as	  influenza	  B,	  can	  be	  screened	  for	  inhibition	  by	  HAI-­‐2.	  Finally,	  protein	  engineering	   of	   HAI-­‐2	   could	   be	   done	   to	   try	   and	   produce	   a	   more	   effective	   version	   of	   the	  protein	  for	  use	  as	  an	  antiviral	  therapeutic.	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